Pyropia yezoensis peptide PYP1‑5 protects against dexamethasone‑induced muscle atrophy through the downregulation of atrogin1/MAFbx and MuRF1 in mouse C2C12 myotubes

Lee,Min‑Kyeong; Kim,Young‑Min; Kim,In‑Hye; Choi,Youn‑Hee; Nam,Taek‑Jeong

doi:10.3892/mmr.2017.6443

Pyropia yezoensis peptide PYP1‑5 protects against dexamethasone‑induced muscle atrophy through the downregulation of atrogin1/MAFbx and MuRF1 in mouse C2C12 myotubes

Authors:
- Min‑Kyeong Lee
- Young‑Min Kim
- In‑Hye Kim
- Youn‑Hee Choi
- Taek‑Jeong Nam
View Affiliations

Affiliations: Department of Food Science and Nutrition, Pukyong National University, Busan 48513, Republic of Korea, Institute of Fisheries Sciences, Pukyong National University, Busan 46041, Republic of Korea
Published online on: April 7, 2017 https://doi.org/10.3892/mmr.2017.6443
Pages: 3507-3514
Copyright: © Lee et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Skeletal muscle atrophy refers to the decline in muscle mass and strength that occurs under various conditions, including aging, starvation, cancer and other cachectic diseases. Muscle atrophy caused by aging, known as sarcopenia, primarily occurs after 50 years of age. Muscle atrophy‑related genes, including atrogin1/muscle atrophy F‑box (MAFbx) and muscle RING finger 1 (MuRF1), are expressed early in the muscle atrophy process, and their expression precedes the loss of muscle mass. The present study investigated the potential anti‑atrophic effects of the Pyropia yezoensis peptide PYP1‑5. The MTS assay did not detect cytotoxic effects of PYP1‑5 on C2C12 mouse myoblast cells. Subsequently, the anti‑atrophic effects of PYP1‑5 on skeletal muscle cells was examined by treating C2C12 myotubes with 100 µM dexamethasone (DEX) and/or 500 ng/ml PYP1‑5 for 24 h. Compared with the control, myotube diameter was reduced in DEX‑treated cells, whereas PYP1‑5 treatment protected against DEX‑induced muscle atrophy. MAFbx and MuRF1 protein and mRNA expression levels were detected by western blot analysis and reverse transcription‑quantitative polymerase chain reaction, respectively. The results demonstrated that PYP1‑5 significantly reduced the expression of atrogin1/MAFbx and MuRF1. Therefore, data from the present study suggest that PYP1‑5 inhibits the expression of atrogin1/MAFbx and MuRF1 in C2C12 cells, and these characteristics may be of value in the development of anti‑atrophy functional foods.

View Figures

View References

1	Byeon Y, Lee H Yool, Choi DW and Back K: Chloroplast-encoded serotonin N-acetyltransferase in the red alga Pyropia yezoensis: Gene transition to the nucleus from chloroplasts. J Exp Bot. 66:709–717. 2015. View Article : Google Scholar : PubMed/NCBI
2	Lee MK, Kim IH, Choi YH, Choi JW, Kim YM and Nam TJ: The proliferative effects of Pyropia yezoensis peptide on IEC-6 cells are mediated through the epidermal growth factor receptor signaling pathway. Int J Mol Med. 35:909–914. 2015.PubMed/NCBI
3	Wenz T, Rossi SG, Rotundo RL, Spiegelman BM and Moraes CT: Increased muscle PGC-1alpha expression protects from sarcopenia and metabolic disease during aging. Proc Natl Acad Sci USA. 106:pp. 20405–20410. 2009; View Article : Google Scholar : PubMed/NCBI
4	Doherty TJ: Invited Review: Aging and sarcopenia. J Appl Physiol (1985). 95:1717–1727. 2003. View Article : Google Scholar : PubMed/NCBI
5	Marzetti E and Leeuwenburgh C: Skeletal muscle apoptosis, sarcopenia and frailty at old age. Exp Gerontol. 41:1234–1238. 2006. View Article : Google Scholar : PubMed/NCBI
6	Dupont-Versteegden EE: Apoptosis in muscle atrophy: Relevance to sarcopenia. Exp Gerontol. 40:473–481. 2005. View Article : Google Scholar : PubMed/NCBI
7	Artaza JN, Bhasin S, Mallidis C, Taylor W, Ma K and Gonzalez-Cadavid NF: Endogenous expression and localization of myostatin and its relation to myosin heavy chain distribution in C2C12 skeletal muscle cells. J Cell Physiol. 190:170–179. 2002. View Article : Google Scholar : PubMed/NCBI
8	Aoki MS, Miyabara EH, Soares AG, Saito ET and Moriscot AS: mTOR pathway inhibition attenuates skeletal muscle growth induced by stretching. Cell Tissue Res. 324:149–156. 2006. View Article : Google Scholar : PubMed/NCBI
9	Weintraub H: The MyoD family and myogenesis: Redundancy, networks, and thresholds. Cell. 75:1241–1244. 1993. View Article : Google Scholar : PubMed/NCBI
10	Melo F, Carey DJ and Brandan E: Extracellular matrix is required for skeletal muscle differentiation but not myogenin expression. J Cell Biochem. 62:227–239. 1996. View Article : Google Scholar : PubMed/NCBI
11	te Pas MF, Soumillion A, Harders FL, Verburg FJ, van den Bosch TJ, Galesloot P and Meuwissen TH: Influences of myogenin genotypes on birth weight, growth rate, carcass weight, backfat thickness, and lean weight of pigs. J Anim Sci. 77:2352–2356. 1999. View Article : Google Scholar : PubMed/NCBI
12	Sandri M, Sandri C, Gilbert A, Skurk C, Calabria E, Picard A, Walsh K, Schiaffino S, Lecker SH and Goldberg AL: Foxo transcription factors induce the atrophy-related ubiquitin ligase atrogin-1 and cause skeletal muscle atrophy. Cell. 177:399–412. 2004. View Article : Google Scholar
13	Zhao W, Qin W, Pan J, Wu Y, Bauman WA and Cardozo C: Dependence of dexamethasone-induced Akt/FOXO1 signaling, upregulation of MAFbx, and protein catabolism upon the glucocorticoid receptor. Biochem Biophys Res Commun. 378:668–672. 2009. View Article : Google Scholar : PubMed/NCBI
14	Glass DJ: Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol. 37:1974–1984. 2005. View Article : Google Scholar : PubMed/NCBI
15	Hershko A and Ciechanover A: The ubiquitin system. Annu Rev Biochem. 67:425–479. 1998. View Article : Google Scholar : PubMed/NCBI
16	Lecker SH, Jagoe RT, Gilbert A, Gomes M, Baracos V, Bailey J, Price SR, Mitch WE and Goldberg AL: Multiple types of skeletal muscle atrophy involve a common program of changes in gene expression. FASEB J. 18:39–51. 2004. View Article : Google Scholar : PubMed/NCBI
17	Meng SJ and Yu LJ: Oxidative stress, molecular inflammation and sarcopenia. Int J Mol Sci. 11:1509–1526. 2010. View Article : Google Scholar : PubMed/NCBI
18	Choi YH, Yamaguchi K, Oda T and Nam TJ: Chemical and mass spectrometry characterization of the red alga Pyropia yezoensis chemoprotective protein (PYP): Protective activity of the N-terminal fragment of PYP1 against acetaminophen-induced cell death in Chang liver cells. Int J Mol Med. 35:271–276. 2015.PubMed/NCBI
19	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
20	Cooper ST, Maxwell AL, Kizana E, Ghoddusi M, Hardeman EC, Alexander IE, Allen DG and North KN: C2C12 co-culture on a fibroblast substratum enables sustained survival of contractile, highly differentiated myotubes with peripheral nuclei and adult fast myosin expression. Cell Motil Cytoskeleton. 58:200–211. 2004. View Article : Google Scholar : PubMed/NCBI
21	Gomes MD, Lecker SH, Jagoe RT, Navon A and Goldberg AL: Atrogin1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci USA. 98:pp. 14440–14445. 2001; View Article : Google Scholar : PubMed/NCBI
22	Auclair D, Garrel DR, Zerouala A Chaouki and Ferland LH: Activation of the ubiquitin pathway in rat skeletal muscle by catabolic doses of glucocorticoids. Am J Physiol. 272:C1007–C1016. 1997.PubMed/NCBI
23	Jackman RW and Kandarian SC: The molecular basis of skeletal muscle atrophy. Am J Physiol. 287:C834–C843. 2004. View Article : Google Scholar
24	Mitch WE and Goldberg AL: Mechanisms of muscle wasting. The role of the ubiquitin-proteasome pathway. N Engl J Med. 335:1897–1905. 1996. View Article : Google Scholar : PubMed/NCBI
25	Krawiec BJ, Nystrom GJ, Frost RA, Jefferson LS and Lang CH: AMP-activated protein kinase agonists increase mRNA content of the muscle-specific ubiquitin ligases MAFbx and MuRF1 in C2C12 cell. Am J Physiol Endocrinol Metab. 292:E1555–E1567. 2007. View Article : Google Scholar : PubMed/NCBI
26	Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Laltres E and Glass DJ: The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle. Cell Metab. 6:376–385. 2007. View Article : Google Scholar : PubMed/NCBI